European Respiratory Society eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 27, 2024
Language: Английский
Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13
Published: March 12, 2025
The advent of mRNA vaccines, accelerated by the global response to COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss development, current applications, and prospects vaccines for both prevention treatment infectious diseases oncology. By leveraging capacity encode antigens within host cells directly, provide versatile scalable platform suitable addressing broad spectrum pathogens tumor-specific antigens. We highlight recent advancements design, innovative delivery mechanisms, ongoing clinical trials, with particular emphasis on their efficacy combating diseases, such as COVID-19, Zika, influenza, well emerging potential cancer immunotherapy. also address critical challenges, including stability, optimization immune responses, broader issue accessibility. Finally, review strategies advancing next-generation aim overcoming limitations technology enhancing preventive therapeutic approaches oncological diseases.
Language: Английский
Citations
1
Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)
Published: Aug. 31, 2024
Abstract Malignant tumors remain a primary cause of human mortality. Among the various treatment modalities for neoplasms, tumor vaccines have consistently shown efficacy and promising potential. These offer advantages such as specificity, safety, tolerability, with mRNA representing platforms. By introducing exogenous mRNAs encoding antigens into somatic cells subsequently synthesizing through gene expression systems, can effectively induce immune responses. Katalin Karikó Drew Weissman were awarded 2023 Nobel Prize in Physiology or Medicine their great contributions to vaccine research. Compared traditional vaccines, several advantages, including rapid preparation, reduced contamination, nonintegrability, high biodegradability. Tumor-targeted therapy is an innovative modality that enables precise targeting cells, minimizes damage normal tissues, safe at doses, demonstrates efficacy. Currently, targeted has become important option malignant tumors. The application tumor-targeted expanding, numerous clinical trials underway. We systematically outline delivery mechanism by which anti-tumor responses, describe current research applications therapy, forecast future development trends therapy.
Language: Английский
Citations
8
Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(9)
Published: Sept. 1, 2024
Abstract Despite remarkable progress in the treatment of hepatitis C virus (HCV) infection, it remains a significant global health burden, necessitating development an effective prophylactic vaccine. This review paper presents current landscape HCV vaccine candidates and approaches, including more traditional, based on inactivated virus, modern, such as subunit protein, vectored, nucleic acids (DNA mRNA) virus‐like particles. The concept is first put context viral genetic diversity adaptive responses to understanding which crucial guiding against complex virus. Because ethical dimensions are also research, development, potential deployment, we address them this paper. road safe prevent infection bumpy due variation its ability evade immune responses. cell‐culture systems allowed for production candidate, can induce cross‐neutralizing antibodies vitro , but whether could humans unknown. Subunit protein that entered clinical trials elicited HCV‐specific humoral cellular responses, though be shown they translate into prevention or progression chronic state. Such were induced by clinically tested vector‐based decreased load did not infection. These disappointments readily predicted from preclinical animal studies. platforms employing particles, DNA, mRNA provide opportunities vaccine, their has yet shown. Ensuring designed conserved epitope(s) elicits broadly neutralizing essential. Given failures developing continue supporting national strategies, funding screening programs. However, these actions likely insufficient permanently control encouraging further mobilization resources research missing element elimination public health.
Language: Английский
Citations
5
Vaccines, Journal Year: 2025, Volume and Issue: 13(1), P. 94 - 94
Published: Jan. 20, 2025
Background: Inefficient cellular uptake is a significant limitation to the efficacy of DNA vaccines. In this study, we introduce S-Cr9T, stearyl-modified cell-penetrating peptide (CPP) designed enhance vaccine delivery by forming stable complexes with plasmid DNA, thereby protecting it from degradation and promoting efficient intracellular uptake. Methods Results: vitro studies showed that S-Cr9T significantly improved stability transfection efficiency, optimal performance at an N/P ratio 0.25. High-content imaging revealed S-Cr9T–plasmid complex stably adhered cell membrane, leading enhanced transfection. vivo, increased antigen expression triggered robust immune response, including threefold increase in IFN-γ secretion several hundred-fold increases antibody levels compared control groups. Conclusions: These findings underscore potential efficacy, offering promising platform for advanced gene therapy vaccination strategies.
Language: Английский
Citations
0
Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)
Published: Jan. 27, 2025
This bibliometric and visualization study provides a comprehensive analysis of global research hotspots trends in DNA vaccine from 2014 to 2024. By employing data sourced the Web Science Core Collection, we identified total 3,600 articles. Our reveals declining trend annual publications. Active countries, institutions, journals, authors were identified, with China, Pasteur Network, Vaccine Journal, David B Weiner being most prolific contributors. Keywords cluster distinguished four major directions: infectious disease immunity, viral challenge development, optimization delivery systems, cancer immunotherapy research. The literature co-citation revealed hotspots, including vaccines for Zika virus, human papillomavirus (HPV), COVID-19, as well safety, efficacy, immunogenicity studies vaccines. Concurrently, burst citation emerging themes, development Ebola, MERS-CoV, innovations antigen design technologies. offers valuable insights into evolution future directions research, emphasizing its importance public health potential address current challenges.
Language: Английский
Citations
0
International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 302, P. 140558 - 140558
Published: Feb. 1, 2025
Language: Английский
Citations
0
Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 151 - 151
Published: Jan. 31, 2025
Q fever is a zoonotic disease caused by the obligate intracellular bacterium Coxiella burnetii that presents significant challenges for global public health control. Current prevention relies primarily on whole-cell vaccine "Q-VAX", which despite its effectiveness, faces important limitations including pre-screening requirements and reactogenicity issues in previously sensitized individuals. This comprehensive review examines complex interplay between pathogen characteristics, host immune responses, development strategies. We analyze recent advances understanding C. burnetii's molecular pathogenesis host-pathogen interactions have informed design. The evolution of approaches evaluated, from traditional preparations to modern subunit, DNA, multi-epitope designs. Particular attention given innovative technologies, reverse vaccinology immunoinformatics, enabled identification novel antigenic targets. Recent clinical data demonstrating safety immunogenicity next-generation candidates are presented, alongside manufacturing implementation considerations. While progress has been made overcoming first-generation vaccines, remain optimizing while ensuring across diverse populations. provides critical analysis current evidence future directions development, highlighting promising strategies achieving more effective broadly applicable vaccines.
Language: Английский
Citations
0
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1170 - 1170
Published: Feb. 11, 2025
Viral infections such as human papillomavirus (HPV) and Epstein–Barr virus (EBV) play a critical role in the onset of oropharyngeal (OPC) nasopharyngeal cancer (NPC), respectively. Despite advancements targeted therapies immunotherapies, recurrent/metastatic setting, these tumors remain incurable diseases with poor prognosis. The development therapeutic tumor vaccines, utilizing either neoantigens or oncoviral antigens, represents promising addition to immunotherapy arsenal. Research on vaccine-based for OPC NPC focuses targeting viral particularly HPV E6/E7 EBV EBNA1/LMP2. potential vaccine platforms, including peptide-based, DNA, RNA, vector-based induce durable immune responses against antigens is reported. early-phase clinical trials evaluating HPV-related EBV-related revealed safety preliminary signs efficacy; however, further are crucial validation. This review provides an overview current landscape strategies NPC, discussing their biological mechanisms processes involved anti-HPV anti-EBV treatments, particular focus factors that influence therapies.
Language: Английский
Citations
0
Viruses, Journal Year: 2025, Volume and Issue: 17(3), P. 330 - 330
Published: Feb. 27, 2025
Highly pathogenic avian influenza (HPAI) H5 clade 2.3.4.4b viruses are widespread in wild and domestic birds, causing severe economic damage to the global poultry industry. Moreover, of this known cause infections mammals, posing a potential pandemic threat. Due ongoing evolution change dominant strains 2.3.4.4b, it is important investigate cross-reactivity vaccines use under development against viruses. In study, immunogenicity previously developed DNA vaccine encoding modified hemagglutinin A/turkey/Stavropol/320-01/2020 (H5N8) virus, administered by jet injection at doses 1, 10, 50, 100, 200 μg, was investigated. The highest titer specific recombinant antibodies detected group animals injected with 100 µg vaccine. study sera immunized microneutralization assay A/chicken/Astrakhan/321-05/2020 (H5N8), A/chicken/Komi/24-4V/2023 (H5N1), A/chicken/Khabarovsk/24-1V/2022 (H5N1) showed formation cross-neutralizing antibodies. protective properties that protected from mortality after infection virus.
Language: Английский
Citations
0
Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0